NeuroPace Faces FDA Challenge on IGE Seizure-Treatment Device

NeuroPace Inc., developer of advanced neuromodulation devices for epilepsy, is advancing its next-generation Responsive Neurostimulation (RNS) System toward FDA approval for idiopathic generalized epilepsy (IGE), a subset of drug-resistant seizures. The company’s management, including CFO Patrick Williams and Head of Investor Relations Scott Schaper, discussed the clinical and regulatory progress at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026. The device’s efficacy hinges on the NAUTILUS trial, which collected 27 million EEG readings and demonstrated a 77% median seizure reduction at 18 months and 100% at 24 months. While the primary efficacy endpoint—time to second generalized tonic-clonic seizure—was not met, secondary outcomes showed a 30% reduction in seizure-related injuries and over 40% decline in rescue medication use, meeting safety targets. The FDA issued a non-approvable letter in late July 2024, prompting NeuroPace to prepare for an early-to-mid-Q4 2024 Submission Issue Request (SIR) meeting. If the agency issues a major amendment, the review clock could extend to Q1 or Q2 2027, delaying approval further. Meanwhile, the company aims to file for FDA clearance of its Remote Care platform by year-end 2024, enabling remote programming and ECoG monitoring. Project CARE, a two-year initiative launched prior to the conference, focuses on expanding access to its devices. The company’s financial outlook remains robust, with revenue growth reaffirmed at 21%–23% for the RNS System in 2024, up from an initial expectation of 20%. Trailing revenue growth over the past 12 months stood at 33%, with gross margins of 77% and non-GAAP guidance of 82%–83%. Pricing growth aligns with CMS reimbursement trends, averaging 150–250 basis points annually. NeuroPace’s market share in the epilepsy neuromodulation space remains under 15%–20%, but its addressable market—including focal epilepsy (48% of drug-resistant cases) and niche indications like Lennox-Gastaut syndrome—is substantial. The company’s stock (NPCE) has returned 53% over the past year, with a beta of 1.95, reflecting volatility. The addressable U.S. market for drug-resistant epilepsy stands at about 1.2 million patients, with roughly 15,000 receiving medical interventions annually. Insurance coverage is split between private pay (50%), traditional Medicare/Medicaid (20%), and Medicare/Medicaid Advantage plans (30%). Competitors include LivaNova’s VNS therapy and Medtronic’s DBS systems, while surgical resection remains an alternative. The company’s battery life—up to 10 years—outlasts competitors’ 3–4-year replacement cycles, a key differentiator. NeuroPace targets cash-flow breakeven by the end of 2027, with replacement revenue constituting less than 10% of total revenue.